Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Have novel drugs made stem cell transplantation obsolete?

David Maloney • 14 Jun 2017
ICML 2017
Non-Hodgkin Lymphoma

David Maloney, MD, PhD from the Fred Hutchinson Cancer Center, Seattle, WA reviews the spirited debate entitled, ‘Have new drugs made stem cell transplantation obsolete’, which took place during the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. The consensus from the debate was that, while the treatment landscape in lymphoma is moving towards more targeted therapies, stem cell transplantation is the only available ‘cure’ for high-risk patients and so it is not superseded by novel agents.

More from David Maloney

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
12:26
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
Alexey Danilov et al. • 11 Apr 2025
Expanding the CAR platform in NHL
Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
Advances in CAR-T therapy for lymphoma
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals